PURPOSE: The aim of the present retrospective study is to evaluate toxicity and early clinical outcomes of interstitial hyperthermia (IHT) combined with high-dose rate (HDR) brachytherapy as a salvage treatment in patients with biopsy-confirmed local recurrence of prostate cancer after previous external beam radiotherapy. PATIENTS AND METHODS: Between September 2008 and March 2013, 25 patients with local recurrence of previously irradiated prostate cancer were treated. The main eligibility criteria for salvage prostate HDR brachytherapy combined with interstitial hyperthermia were biopsy confirmed local recurrence and absence of nodal and distant metastases. All patients were treated with a dose of 30 Gy in 3 fractions at 21-day intervals. We performed 62 hyperthermia procedures out of 75 planned (83 %). The aim of the hyperthermia treatment was to heat the prostate to 41-43 °C for 60 min. Toxicity for the organs of the genitourinary system and rectum was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, v. 4.03). Determination of subsequent biochemical failure was based on the Phoenix definition (nadir + 2 ng/ml). RESULTS: The median age was 71 years (range 62-83 years), the median initial PSA level was 16.3 ng/ml (range 6.37-64 ng/ml), and the median salvage PSA level was 2.8 ng/ml (1.044-25.346 ng/ml). The median follow-up was 13 months (range 4-48 months). The combination of HDR brachytherapy and IHT was well tolerated. The most frequent complications were nocturia, weak urine stream, urinary frequency, hematuria, and urgency. Grade 2 rectal hemorrhage was observed in 1 patient. No grade 3 or higher complications were observed. The 2-year Kaplan-Meier estimate of biochemical control after salvage treatment was 74 %. The PSA in 20 patients decreased below the presalvage level, while 11 patients achieved a PSA nadir < 0.5 ng/ml. All patients are still alive. Of the 7 patients who experienced biochemical failure, bone metastases were found in 2 patients. CONCLUSION: IHT in combination with salvage HDR brachytherapy is a well tolerated and effective treatment.
PURPOSE: The aim of the present retrospective study is to evaluate toxicity and early clinical outcomes of interstitial hyperthermia (IHT) combined with high-dose rate (HDR) brachytherapy as a salvage treatment in patients with biopsy-confirmed local recurrence of prostate cancer after previous external beam radiotherapy. PATIENTS AND METHODS: Between September 2008 and March 2013, 25 patients with local recurrence of previously irradiated prostate cancer were treated. The main eligibility criteria for salvage prostate HDR brachytherapy combined with interstitial hyperthermia were biopsy confirmed local recurrence and absence of nodal and distant metastases. All patients were treated with a dose of 30 Gy in 3 fractions at 21-day intervals. We performed 62 hyperthermia procedures out of 75 planned (83 %). The aim of the hyperthermia treatment was to heat the prostate to 41-43 °C for 60 min. Toxicity for the organs of the genitourinary system and rectum was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, v. 4.03). Determination of subsequent biochemical failure was based on the Phoenix definition (nadir + 2 ng/ml). RESULTS: The median age was 71 years (range 62-83 years), the median initial PSA level was 16.3 ng/ml (range 6.37-64 ng/ml), and the median salvage PSA level was 2.8 ng/ml (1.044-25.346 ng/ml). The median follow-up was 13 months (range 4-48 months). The combination of HDR brachytherapy and IHT was well tolerated. The most frequent complications were nocturia, weak urine stream, urinary frequency, hematuria, and urgency. Grade 2 rectal hemorrhage was observed in 1 patient. No grade 3 or higher complications were observed. The 2-year Kaplan-Meier estimate of biochemical control after salvage treatment was 74 %. The PSA in 20 patients decreased below the presalvage level, while 11 patients achieved a PSA nadir < 0.5 ng/ml. All patients are still alive. Of the 7 patients who experienced biochemical failure, bone metastases were found in 2 patients. CONCLUSION: IHT in combination with salvage HDR brachytherapy is a well tolerated and effective treatment.
Authors: B Emami; P Stauffer; M W Dewhirst; S Prionas; T Ryan; P Corry; T Herman; D S Kapp; R J Myerson; T Samulski Journal: Int J Radiat Oncol Biol Phys Date: 1991-05 Impact factor: 7.038
Authors: S Maluta; S Dall'Oglio; M Romano; N Marciai; F Pioli; M G Giri; P L Benecchi; L Comunale; A B Porcaro Journal: Int J Hyperthermia Date: 2007-08 Impact factor: 3.914
Authors: Elnasif Arrayeh; Antonio C Westphalen; John Kurhanewicz; Mack Roach; Adam J Jung; Peter R Carroll; Fergus V Coakley Journal: Int J Radiat Oncol Biol Phys Date: 2012-02-11 Impact factor: 7.038
Authors: Piyush K Agarwal; Natalia Sadetsky; Badrinath R Konety; Martin I Resnick; Peter R Carroll Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Andrzej M Kukiełka; Vratislav Strnad; Paul Stauffer; Tomasz Dąbrowski; Marcin Hetnał; Damian Nahajowski; Tomasz Walasek; Piotr Brandys; Robert Matys Journal: J Contemp Brachytherapy Date: 2015-05-28
Authors: Romuald Zdrojowy; Janusz Dembowski; Bartosz Małkiewicz; Krzysztof Tupikowski; Wojciech Krajewski Journal: Cent European J Urol Date: 2016-07-04
Authors: Morgan Michalet; Olivier Riou; Simon Valdenaire; Pierre Debuire; Norbert Ailleres; Roxana Draghici; Marie Charissoux; Carmen Llacer Moscardo; Marie-Pierre Farcy-Jacquet; Pascal Fenoglietto; David Azria Journal: Adv Radiat Oncol Date: 2021-07-01
Authors: Jim Zhong; Finbar Slevin; Andrew F Scarsbrook; Maria Serra; Ananya Choudhury; Peter J Hoskin; Sarah Brown; Ann M Henry Journal: Front Oncol Date: 2021-09-09 Impact factor: 6.244
Authors: Ioannis Androulakis; Rob M C Mestrom; Miranda E M C Christianen; Inger-Karine K Kolkman-Deurloo; Gerard C van Rhoon Journal: Cancers (Basel) Date: 2022-03-10 Impact factor: 6.639